CTI Life Sciences Fund
Edit

CTI Life Sciences Fund

http://www.ctisciences.com/
Last activity: 11.03.2024
Active
Invests in categories: BioTechBusinessDesignDevelopmentInterestITLifeLivingMedTechProduct
Where broad venture capital, operational and governance experience come together to catalyze, transform and invest in existing and future Life Science companies.
News
61
Portfolio
3
Mentions
21
Employees: 1-10
Investment Type: Venture Capital

Portfolio 3

DateNameWebsiteTotal RaisedLocation
09.01.2023Amolyt Pha...amolytpharma.com$218MFrance, Au...
04.06.2021VectivBio ...vectivbio.com$324MSwitzerlan...
-Find Thera...findtherapeutics.com-Canada, Qu...

News 61

DateTitleDescription
21.01.2022Québec accorde 15 M$ supplémentaires au Fonds CTI Sciences de la vie III-
31.08.2021Luca Santarelli's VectivBio buys out small Massachusetts biotech, redoubling focus on metabolic disease-
12.05.2021Recent news coverage relating to the close of our third fund:-
10.05.2021CTI Life Sciences Fund Successfully Raises $100 Million As A First Tranche of its Third Venture Capital Fund-
08.02.2021Bristol Myers Squibb Receives European Commission Approval for Inrebic® (fedratinib) for Adult Patients with Newly Diagnosed and Previously Treated Myelofibrosis-
03.02.2021VectivBio Announces First Patient Dosed in Pivotal Phase 3 Trial of Apraglutide for the Treatment of Short Bowel Syndrome-
15.12.2020Pfizer Doses First Patients as Part of Global Achondroplasia Phase 2 Development Program-
04.11.2020VectivBio Strengthens Business Development Capabilities with Key Appointments-
08.06.2020Find Therapeutics, a new drug development company dedicated to breakthrough therapies against rare diseases launches in Montreal-
08.05.2019Pfizer Acquires Clinical-Stage Biotech Therachon-
Show more

Mentions in press and media 21

DateTitleDescription
11.03.2024AbilityPharma cierra una ronda de €7M liderada por CTI Life Sciences Fund, Inveready y EIC Fund. Participan CDTI Innvierte, FiTalent, fundadores y CapitalCell11/03/2024 Nota de prensa ABILITYPHARMA CIERRA UNA RONDA DE €7M PARA EL FÁRMACO ABTL0812 EN FASE CLÍNICA 2B EN CÁNCER DE PÁNCREAS METASTÁTICO El fondo de capital riesgo (venture capital) canadiense CTI Life Sciences Fund, Inveready y el EIC...
12.01.2023French pharma Amolyt nets €130 million series C co-led by Sofinnova PartnersAmolyt Pharma, an Ecully, France-based pharma startup working on rare disease treatments, has closed a €130 million series C round. Amolyt is targeting rare indications affecting the body's hormone supply from endocrine glands. The series C...
25.04.2022Advancing cancer treatments, medtech startup Epitopea raises £10.3 millionCambridge-based Epitopea has raised £10.3 million in a seed funding round. The medtech startup is developing off-the-shelf cancer immunotherapies designed to treat a broad patient population. The influx of capital will be used to further ad...
10.05.2021CTI Life Sciences Fund raises $100 million in first close of third venture fundMontréal-based venture capital firm CTI Life Sciences Fund has raised $100 million CAD in the first close of its third venture fund. The fund’s limited partners include previous investors such as Fonds de solidarité FTQ, Caisse de dépôt et ...
10.05.2021CTI Life Sciences Fund Successfully Raises $100 Million As A First Tranche of its Third Venture Capital Fund-
10.05.2021CTI Life Sciences Fund secures initial C$100m for third pool-
09.07.2020THE BLACKSTONE GROUP INC. Blackstone : Announces $4.6 Billion Final Close of Life Sciences FundBlackstone (NYSE: BX) today announced the final close of Blackstone Life Sciences V (“BXLS V”), the inaugural Blackstone fund in Life Sciences. BXLS V was oversubscribed and closed at its hard cap of $4.6 billion of total capital commitment...
08.06.2020Find Therapeutics, a new drug development company dedicated to breakthrough therapies against rare diseases launches in MontrealThe new company raises initial capital to develop transmembrane peptides against GPCRs to address high unmet needs. Montreal, Canada – June 8, 2020: CTI Life Sciences, along with partners adMare BioInnovations, Domain Therapeutics and Pepti...
06.05.2016 Amgen Backs New $315M Life Sciences Fund Thousand Oaks-based Amgen has helped to back a new, life sciences fund, managed by San Francisco-based venBio, as an anchor supporter of a new fund. venBio said Friday that it has closed a $315M life sciences fund, venBio Global Strategic F...
10.07.2015Xagenic Raises CAD$15M in FundingXagenic, a Toronto, Canada-based molecular diagnostics company developing the lab-free Xagenic X1™ platform for use at the point of care, raised CAD$15M in funding. Backers included Domain Associates, CTI Life Sciences, BDC Capital and the ...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In